Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Noa Lowenton-Spier"'
Autor:
Svetlana Trestman, Irit Avivi, Moshe Mittelman, Tamir Shragai, Chava Perry, Yaara Tabib, Yair Herishanu, Tali Bar Lev, Yael C Cohen, Noa Lowenton-Spier, Noam Benyamini, Roi Balaban, Miguel Morales, Gabi Sheffer, Anat Aharon, Efrat Luttwak, Mor Zavaro
Publikováno v:
British Journal of Haematology
Summary Multiple myeloma (MM) patients are at excess risk for clinically significant COVID19 infection. BNT162b2 mRNA COVID19 (BNT162b2) vaccine provides effective protection against COVID19 for the general population, yet its effect in MM patients m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1c451233c0d41c763908d9024d6f6a5
https://doi.org/10.1111/bjh.17608
https://doi.org/10.1111/bjh.17608
Autor:
Yael C Cohen, Tamir Shragai, Noa Lavi, Iuliana Vaxman, Evgeni Chubar, Moshe E Gatt, Chezi Ganzel, Hila Magen, Efrat Luttwak, Noa Lowenton-Spier, Liron Gez-Aaronson, Natan Melamed, Irit Avivi
Publikováno v:
Blood. 140:10131-10132
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::727c1d55467f882a19513343e522601c
https://doi.org/10.1182/blood-2022-164722
https://doi.org/10.1182/blood-2022-164722
Autor:
Yael C Cohen, Moshe E Gatt, Efrat Luttwak, Noa Lavi, Chezi Ganzel, Evgeni Chubar, Ory Rouvio, Iuliana Vaxman, Oren Pasvolsky, Mouna Ballan, Tamar Tadmor, Anatoly Nemets, Osnat Jarchowsky, Olga Shvetz, Ofer Shpilberg, Najib Dally, Merav Leiba, Assaf Weiner, Mor Zada, Shuang-Yin Wang, Chamutal Gur, Noa Lowenton-Spier, Liron Goor-Porges, Ido Amit, Irit Avivi
Publikováno v:
Blood. 140:4426-4427
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e1ab7c401c8e4bb38624cc3dc8e16a1
https://doi.org/10.1182/blood-2022-164572
https://doi.org/10.1182/blood-2022-164572
Autor:
Jian Campian, Andrew Brenner, Patrick Y. Wen, Shifra Fain Shmueli, John de Groot, Tamar Rachmilewitz Minei, Laurence S. Freedman, Noa Lowenton-Spier, Leor Zach, Nicholas Butowski, Timothy F. Cloughesy, Benjamin M. Ellingson, Yael C Cohen
Publikováno v:
Neuro-Oncology. 22:705-717
BackgroundOfranergene obadenovec (VB-111) is an anticancer viral therapy that demonstrated in a phase II study a survival benefit for patients with recurrent glioblastoma (rGBM) who were primed with VB-111 monotherapy that was continued after progres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0a1a4a7731cf802c2985f90ac93b982
https://doi.org/10.1093/neuonc/noz232
https://doi.org/10.1093/neuonc/noz232
Autor:
Chencai Wang, Kunal S. Patel, Jian Campian, Timothy F. Cloughesy, Shan Rizvi, Patrick Y. Wen, Noa Lowenton-Spier, Leor Zach, Andrew Brenner, Tamar Rachmilewitz Minei, Yael C Cohen, Nicholas Butowski, Benjamin M. Ellingson, Catalina Raymond, John de Groot, Jacob Schlossman, Shifra Fain Shmueli
Publikováno v:
Neuro-oncology advances, vol 3, iss 1
Neuro-oncology Advances
Neuro-oncology Advances
Background Evidence from single and multicenter phase II trials have suggested diffusion MRI is a predictive imaging biomarker for survival benefit in recurrent glioblastoma (rGBM) treated with anti-VEGF therapy. The current study confirms these find
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a33780ff3ae4736d8bd0e2fe95b2f023
https://escholarship.org/uc/item/05g831w8
https://escholarship.org/uc/item/05g831w8
Autor:
Shan Rizvi, Kunal S. Patel, Jian Campian, Leor Zach, Catalina Raymond, Chencai Wang, Timothy F. Cloughesy, Jacob Schlossman, Nicholas Butowski, Yael Cohen, Noa Lowenton-Spier, Andrew Brenner, John de Groot, Benjamin M. Ellingson, Tamar Rachmilewitz Minei, Shifra Fain-Shmueli, Patrick Y. Wen
Publikováno v:
Neuro Oncol
BACKGROUND Evidence from independent single center as well as multicenter phase II trials have suggested diffusion MRI is a strong predictive imaging biomarker for survival benefit in recurrent glioblastoma (rGBM) treated with anti-VEGF monotherapy,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29489d2f1ae5aad4638947e3c7699b56
https://europepmc.org/articles/PMC7651187/
https://europepmc.org/articles/PMC7651187/
Autor:
Timothy F. Cloughesy, Laurence S. Freedman, Felix Bokstein, Benjamin M. Ellingson, Andrew Brenner, Katherine B. Peters, Naamit Sher, Eyal Breitbart, Shlomit Yust-Katz, Patrick Y. Wen, Itzhak Mendel, Bernice Oberman, Idit Peretz, Tamar Rachmilewitz Minei, Niva Yakov, James J. Vredenburgh, Deborah T. Blumenthal, Yael C Cohen, Noa Lowenton-Spier
Publikováno v:
Neuro-oncology, vol 22, iss 5
Neuro-Oncology
Neuro-Oncology
Background VB-111 is a non-replicating adenovirus carrying a Fas-chimera transgene, leading to targeted apoptosis of tumor vascular endothelium and induction of a tumor-specific immune response. This phase I/II study evaluated the safety, tolerabilit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f46c0464ac87173392444905e4373dc6
https://escholarship.org/uc/item/269665k9
https://escholarship.org/uc/item/269665k9
Autor:
Yael C Cohen, Noa Lowenton-Spier, Patrick Y. Wen, Timothy F. Cloughesy, Nicholas Butowski, Andrew Brenner
BACKGROUND: Ofranergene obadenovec (VB-111) is a viral cancer-therapy with a dual mechanism: vascular disruption and induction of a tumor directed immune response. In a phase 2 trial, recurrent GBM (rGBM) patients treated with VB-111, followed at pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19157307fda9617251d46050af57b3fb
https://europepmc.org/articles/PMC6216132/
https://europepmc.org/articles/PMC6216132/
Autor:
Yael C Cohen, Laurence S. Freedman, Bradley J. Monk, Thomas J. Herzog, Noa Lowenton-Spier, Dror Harats, Kathleen N. Moore, Richard T. Penson, Robert A. Burger, Naamit Sher
Publikováno v:
Journal of Clinical Oncology. 36:TPS5609-TPS5609
TPS5609Background: Ofranergene obadenovec (VB-111) is a targeted anti-cancer gene therapy with a dual mechanism: an antiangiogenic broad effect and induction of a tumor directed viral immune respon...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba157618461ede3478a89c75f6c9bf41
https://doi.org/10.1200/jco.2018.36.15_suppl.tps5609
https://doi.org/10.1200/jco.2018.36.15_suppl.tps5609
Autor:
Deborah T. Blumenthal, Laurence S. Freedman, Bernice Oberman, Andrew Brenner, Dror Harats, James J. Vredenburgh, Patrick Y. Wen, Michal Lavi, Noa Lowenton-Spier, Yael C Cohen, Katherine B. Peters
Publikováno v:
Journal of Clinical Oncology. 35:2055-2055
2055 Background: Ofranergene obadenovec (VB-111) is a viral cancer-therapy with a dual mechanism: vascular disruption and induction of a tumor directed immune response. Prolongation of overall survival (OS) has been shown in recurrent glioblastoma (r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ae946dd43c2e7b3944d0186d3c88ab5
https://doi.org/10.1200/jco.2017.35.15_suppl.2055
https://doi.org/10.1200/jco.2017.35.15_suppl.2055